Structure Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GPCR research report →
Range $70 – $145
Price Chart
About the company
Structure Therapeutics Inc. , an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R).
- CEO
- Raymond C. Stevens
- IPO
- 2023
- Employees
- 233
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on GPCR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.93B
- P/E
- -16.82
- Fwd P/E
- 47.73
- PEG
- 1.19
- P/S
- 0.00
- P/B
- 2.73
- EV/EBITDA
- -12.56
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -16.91%
- ROIC
- -18.95%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-3,899,285+0.0%
- Op Income
- $-287,567,533
- Net Income
- $-141,202,000-15.2%
- EPS
- $-2.40-2.6%
- OCF Growth
- -90.5%
- FCF Growth
- -91.5%
- 52W High
- $94.90
- 52W Low
- $18.26
- 50D MA
- $49.73
- 200D MA
- $53.53
- Beta
- -1.51
- RSI (14)
- 49
- Avg Volume
- 700.01K
No earnings-call transcripts are available for GPCR yet.
- Free Float
- 95.1%
- Shares Outstanding
- 57.57M
- Float Shares
- 54.73M
of shares held by institutions
210 13F filers
Buy/sell ratio 0.53. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for GPCR, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Thomas R. CarperSenate · DE | Sell | Oct 4, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group PLC | 5.35M | ▲ 264.83K |
| Capitolis Liquid Global Markets LLC | 878.30K | ▲ 878.30K |
| Point72 Europe (London) Llp | 116.70K | 0 |
| Cubist Systematic Strategies, LLC | 16.31K | ▼ 55.38K |
| Good Life Advisors, LLC | 15.00K | ▲ 2.00K |
| Janney Capital Management LLC | 8.51K | ▼ 5.21K |
| Cwm, LLC | 125 | ▼ 355 |
| Point72 Asia (Singapore) Pte. Ltd. | 1 | 0 |
Held by 70 ETFs
Biggest fund positions in GPCR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 18, 26 | Lin Xichen | other | 11,817 |
| Aug 18, 26 | Lin Xichen | other | 11,817 |
| Aug 18, 26 | Lin Xichen | other | 11,817 |
| Aug 18, 26 | Lin Xichen | other | 3,939 |
| Aug 18, 26 | Lin Xichen | sell | 3,020 |
| Aug 18, 26 | Lin Xichen | sell | 519 |
| Aug 18, 26 | Lin Xichen | sell | 400 |
| Aug 6, 26 | Berrios John Joseph | other | 174,612 |
| Aug 6, 26 | Berrios John Joseph | other | 140,766 |
| Aug 6, 26 | Berrios John Joseph | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GPCR coverage
Recent articles, reports, and earnings notes.
Want a deeper read on GPCR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?
zacks.com · Aug 17
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profi
gurufocus.com · Aug 10
The Next Phase Of The Obesity Drug Race
youtube.com · Jun 13
Structure Therapeutics: My Top Small-Cap Pick For The Obesity Market (Upgrade)
seekingalpha.com · Jun 11
Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com · Jun 9
Structure's experimental obesity pill shows no signs of liver injury
reuters.com · Jun 5
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity
globenewswire.com · Jun 5
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
globenewswire.com · May 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.